EFFICACY AND SAFETY OF PREDNISONE-CYCLOPHOSPHAMIDE COMBINATION AS 1ST LINE THERAPY IN 7 PATIENTS WITH ACQUIRED FACTOR-VIII INHIBITORS

被引：0
|
作者：
BERRUT, G
SHOAAY, I
DUPUIS, JM
MAIGRE, M
FRESSINAUD, P
FRESSINAUD, E
机构：
[1] CHU ANGERS,F-49036 ANGERS,FRANCE
[2] CTR HOSP SAUMUR,SAUMUR,FRANCE
[3] CTR TRANSFUS,ANGERS,FRANCE
来源：
THROMBOSIS AND HAEMOSTASIS | 1993年 / 69卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1105 / 1105
页数：1
相关论文
共 50 条
  • [31] A randomized phase III study to compare efficacy and safety between combination therapy and monotherapy as first-line chemotherapy in elderly patients with advanced gastric cancer (KCSG ST13-10)
    Choi, I.
    Lee, K-W.
    Zang, D. Y.
    Ryu, M. H.
    Han, H. S.
    Kim, K. H.
    Kim, M-J.
    Koh, S. A.
    Lee, S. S.
    Koo, D-H.
    Ko, Y. H.
    Sohn, B. S.
    Park, J. H.
    Kim, J. W.
    ANNALS OF ONCOLOGY, 2021, 32 : S1041 - S1041
  • [32] Safety run-in results from phase 3 study of canakinumab (CAN) or placebo in combination with pembrolizumab (PEM) plus platinum based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC (CANOPY-1)
    Johnson, Bruce E.
    Kim, Tae Min
    Hiltermann, T. Jeroen N.
    Barlesi, Fabrice
    Grohe, Christian
    Goto, Yasushi
    Gunnarsson, Orvar
    Overbeck, Tobias
    Reguart, Noemi
    Wermke, Martin
    Castro, Gilberto
    Felip, Enriqueta
    Greystoke, Alastair
    Solomon, Benjamin J.
    Nebot, Noelia
    Deudon, Stephanie
    Louveau, Anne-Laure
    Passos, Vanessa Q.
    Tan, Daniel S. W.
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [33] Study of efficacy and safety of combination of octreotide acetate LAR with lenvatinib as second-line therapy in patients with advanced G1-G2 NETs of non-pancreatic origin
    Goel, V.
    Patnaik, N.
    Talwar, V.
    Chaudhari, K.
    Koyyala, V.
    Goyal, P.
    ANNALS OF ONCOLOGY, 2021, 32 : S166 - S166
  • [34] Efficacy of 2nd line treatment with chemotherapy (CT) or immune checkpoint inhibitors (ICIs) for patients (pts) with a prolonged objective response (>6 months) after 1st line therapy for recurrent or metastatic head & neck squamous cell carcinoma (R/M-HNSCC)
    Vienne, A.
    Collet, L.
    Chevalier, T.
    Borel, C.
    Tardy, M. P.
    Huguet, F.
    Richard, S.
    Salas, S.
    Saada-Bouzid, E.
    Fayette, J.
    Daste, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S666 - S666
  • [35] Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with chemotherapy as first-line therapy
    Li, Haixia
    Wang, Chenyu
    Wang, Ziqi
    Hu, Yabo
    Zhang, Guowei
    Zhang, Mina
    Zheng, Xuanxuan
    Zhang, Xiaojuan
    Yang, Jinbo
    Ma, Zhiyong
    Wang, Huijuan
    LUNG CANCER, 2019, 130 : 42 - 49
  • [36] Toxicity and efficacy of 1st line cetuximab (cetux)-based therapy in RAS wildtype (WT) older patients (pts) with metastatic colorectal cancer (mCRC): A pooled analysis from 1,274 pts in the ARCAD database
    Papamichael, D.
    Lopes, G. S.
    Olswold, C. L.
    Chibaudel, B.
    Zalcberg, J. R.
    Van Cutsem, E.
    Venook, A.
    Maughan, T.
    Heinemann, V.
    Kaplan, R. S.
    Bokemeyer, C.
    Lenz, H. J.
    Yoshino, T.
    Adams, R. A.
    Grothey, A.
    De Gramont, A.
    Shi, Q.
    ANNALS OF ONCOLOGY, 2020, 31 : S425 - S425
  • [37] Efficacy and Safety at 12 Months of 1st Line Bevacizumab (Bv) Plus Chemotherapy (CT) in Elderly Patients (Pt) With Metastatic Colorectal Cancer (mCRC) in Daily Clinical Practice - the CONCERT French Observational Cohort Study
    Bennouna, J.
    Phelip, J. M.
    Andre, T.
    Asselain, B.
    Senellart, H.
    Morsli, O.
    Commenges, B.
    Ducreux, M.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S426 - S426
  • [38] CANOPY-1: Safety run-in results from phase (ph) 3 study of canakinumab (CAN) or placebo (PBO) in combination (comb) with pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) as 1st line therapy in patients (pts) with advanced or metastatic NSCLC
    Grohe, C.
    Johnson, B. E.
    Kim, T. M.
    Hiltermann, T. J. N.
    Barlesi, F.
    Goto, Y.
    Gunnarsson, O.
    Overbeck, T.
    Reguart, N.
    Wermke, M.
    de Castro, G., Jr.
    Felip, E.
    Greystoke, A.
    Solomon, B. J.
    Deudon, S.
    Louveau, A. -L.
    Passos, V.
    Tan, D. S. W.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 152 - 152
  • [39] Ribociclib-endocrine therapy (ET) combination versus chemotherapy as 1st line treatment in patients (pts) with visceral metastatic breast cancer (BC). A multicenter, randomized phase III trial: SAKK 21/18
    Schwitter, Michael
    Zaman, Khalil
    Jerusalem, Guy
    Cazzaniga, Marina
    Greil, Richard
    Ursula, Ursula Strub
    Mueller, Andreas
    Nussbaum, Catrina Uhlmann
    Auteri, Agnes
    Rothgiesser, Karin
    Dietrich, Daniel
    Ruhstaller, Thomas
    CANCER RESEARCH, 2021, 81 (04)
  • [40] EREMISS trial: A double-blind placebo (PBO)- controlled randomised trial assessing efficacy/safety of regorafenib (REGO) as maintenance therapy after 1st line doxorubicin-based chemotherapy in advanced soft-tissue sarcoma (ASTS) patients (pts)
    Penel, N.
    Italiano, A.
    Wallet, J.
    Chaigneau, L.
    Verret, B.
    Firmin, N.
    Watson, S.
    Valentin, T.
    Bompas, E.
    Bertucci, F.
    Brahmi, M.
    Le Cesne, A.
    Brunot, A.
    Ceruso, M. Spalato
    Vanseymortier, M.
    Decoupigny, E.
    Taieb, S.
    Le Deley, M-C.
    Perrin, C.
    Blay, J-Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S1030 - S1030
12345